What You Need to Know
RSV immunisation with nirsevimab significantly reduced hospitalizations, showing 79% overall effectiveness across three European countries.
Protection gradually waned over time, decreasing from 85% in the first month to 69% after three months.
Effectiveness remained high in the youngest infants, with 80% protection in babies aged 0–6 months, underscoring the value of early immunisation.
Study Specifics
Using data from the 3 aforementioned countries, the investigators conducted a case-control study that included 4,102 hospitalized children under the age of 2. Of these, 791 tested positive for RSV and 1,410 children who tested negative served as controls.1
In the study, children were considered immunized if they received nirsevimab between September 2024 and May 2025 before testing, regardless of the dose, or their age and weight at the time of immunization.1
Other Takeaways
Since 2022, the European Union has authorized several immunisation products to prevent RSV disease in infants and older adults. These include long-acting monoclonal antibodies administered to newborns during the winter season and vaccines given to pregnant individuals to protect their infants during the first months of life. RSV circulation in Europe has returned to its pre-pandemic pattern, generally spanning October through April.2
Protection declined progressively over time: 85% effectiveness within the first month after immunization, 78% between 30 and 89 days, and 69% between 90 and 215 days. Among infants aged 0–6 months—the group at highest risk for severe outcomes—overall effectiveness remained high at 80%.1
The authors note that monitoring durability of protection across future seasons will be essential. As such a core European Union 2025–26 protocol has been developed based on lessons learned from this pilot study to improve data collection, increase the sample size at the site level and extend the study to more sites for more precise estimates by time since immunization.
About Nirsevimab
The FDA approved nirsevimab in July of 2023 for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.3
Nirsevimab is a single-dose long-acting monoclonal antibody provided directly to newborns and infants as a single dose, and offers rapid protection to help prevent LRTD caused by RSV, without requiring activation of the immune system.3
References
1.Savulescu C, Ganser I, Nicolay N, et al. Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025. Euro Surveill. 2025;30(45):10.2807/1560-7917.ES.2025.30.45.2500816. doi:10.2807/1560-7917.ES.2025.30.45.2500816
2.Study in Europe: monoclonal antibodies effectively prevent respiratory syncytial virus in infants. Eurkealrert press release. November 13, 2025. Accessed November 17, 2025.
https://www.eurekalert.org/news-releases/1105935
3. Parkinson J. FDA Approves Nirsevimab for RSV in Infants. Contagion. July 17, 2023. Accessed November 17, 2025. https://www.contagionlive.com/view/fda-approves-nirsevimab-for-rsv-in-infants